AUPH Aurinia Pharmaceuticals Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
AUPH Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$14.53
Analyst Target
$16.67
+14.7%
Upside
52W High
$16.54
52W Low
$6.55
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$1.92B
P/E
26.42
ROE
20.7%
Profit margin
29.3%
Debt/Equity
0.21
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
68%
Analysis Accuracy
AUPH exhibits mixed financial health with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, and no available Altman Z-Score limits distress risk assessment. The company shows robust profitability (ROE: 20.65%, Gross Margin: 80.16%) and strong recent earnings growth (YoY EPS +130%), yet trades above its Graham Number of $5.86 at a current price of $14.53, supported by a forward P/E of 15.54 that reflects growth optimism. Insider activity is bearish with recent selling, and technical trend is weak at 10/100, offsetting positive momentum from 1Y return of +81%. Analyst target of $16.67 suggests upside potential, but limited analyst coverage (6) and missing financial data constrain conviction.
Key Strengths
Strong profitability metrics: Gross Margin of 80.16%, Operating Margin of 40.49%, and ROE of 20.65% signal efficient operations.
Exceptional earnings growth: YoY EPS growth of 130% and Q/Q EPS growth of 119.9% reflect accelerating profitability.
Solid balance sheet: Current Ratio of 5.76 and Quick Ratio of 5.02 indicate strong liquidity and low near-term financial risk.
Low leverage: Debt/Equity ratio of 0.21 suggests conservative capital structure and low default risk.
Revenue visibility: Consistent revenue growth (8.40% YoY) and a history of earnings beats (3 out of last 4 quarters) enhance predictability.
Key Risks
Weak Piotroski F-Score of 4/9 indicates suboptimal financial strength, particularly in earnings stability and leverage trends.
Missing key financial data (Total Cash, Debt, EV, ROIC, Free Cash Flow) limits comprehensive health assessment and raises transparency concerns.
Bearish insider sentiment: Net selling of $0.21M by an officer in the last 6 months suggests lack of confidence at the executive level.
Overvaluation relative to defensive metrics: Current price of $14.53 is significantly above Graham Number of $5.86, implying high growth dependency.
Weak technical trend: Technical score of 10/100 and recent 1-month decline of -10.7% signal deteriorating market sentiment.
AI Fair Value Estimate
Based on comprehensive analysis
$16.23
+11.7% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
51
Moderate
52
78
66
58
0
AI Verdict
Cautiously optimistic with data gaps and mixed signals
Key drivers: High profitability and earnings growth, Low debt and strong liquidity, Bearish insider activity, Missing financial data, Overvaluation relative to Graham metric
Confidence
70%
Value
52/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 15.54 is reasonable for a growth-stage biotech
- Trading below analyst target of $16.67
Watchpoints
- Current price ($14.53) is 147% above Graham Number ($5.86)
- P/E of 26.42 is high relative to earnings stability
Future
78/100
Ref Growth rates
Positives
- YoY Earnings Growth of 130.00%
- Q/Q Earnings Growth of 119.90%
- Forward P/E compression suggests improving efficiency
Watchpoints
- PEG Ratio not available, limiting growth-adjusted valuation
Past
66/100
Ref Historical trends
Positives
- History of earnings beats: 3 of last 4 quarters exceeded estimates
- Average earnings surprise of 37.61% over last 4 quarters
- Progression from losses to profitability since 2022
Watchpoints
- Inconsistent quarterly performance with prior losses and volatility
Health
58/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 4/9 indicates stable, not weak, financial condition
- Current Ratio (5.76) and Quick Ratio (5.02) are excellent
- Debt/Equity of 0.21 is very low
Watchpoints
- Piotroski score below 7 signals suboptimal financial strength
- No Altman Z-Score available for distress risk analysis
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend policy: Dividend Strength 0/100, Yield N/A, Payout Ratio 0%
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$14.53
Analyst Target
$16.67
Upside/Downside
+14.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AUPH and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AUPH
Aurinia Pharmaceuticals Inc.
Primary
|
-22.4% | +77.0% | +81.0% | +62.7% | -10.7% | -2.1% |
|
ATRC
AtriCure, Inc.
Peer
|
-33.0% | -7.6% | -3.2% | +24.0% | -3.6% | +0.0% |
|
ADUS
Addus HomeCare Corporation
Peer
|
-6.0% | +1.0% | +11.6% | -8.1% | -10.1% | -1.8% |
|
ANAB
AnaptysBio, Inc.
Peer
|
+227.2% | +183.1% | +284.9% | +177.0% | +17.3% | +17.0% |
|
AZTA
Azenta, Inc.
Peer
|
-50.6% | -29.6% | -26.9% | +16.3% | +16.1% | +0.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
26.42
Forward P/E
15.54
PEG Ratio
N/A
P/B Ratio
5.24
P/S Ratio
7.21
EV/Revenue
6.18
EV/EBITDA
16.33
Market Cap
$1.92B
Profitability
Profit margins and return metrics
Profit Margin
29.28%
Operating Margin
40.49%
Gross Margin
80.16%
ROE
20.65%
ROA
9.41%
Growth
Revenue and earnings growth rates
Revenue Growth
+8.4%
Earnings Growth
+130.0%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+119.9%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.21
Low debt
Current Ratio
5.76
Strong
Quick Ratio
5.02
Excellent
Cash/Share
$2.67
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-26
$N/A
2025-11-04
$0.23
+43.8% surprise
2025-07-31
$0.16
+9.1% surprise
2025-05-12
$0.16
+60.0% surprise
Healthcare Sector Comparison
Comparing AUPH against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
P/E Ratio
26.42
This Stock
vs
164.56
Sector Avg
-83.9%
(Discount)
Return on Equity (ROE)
20.65%
This Stock
vs
-52.77%
Sector Avg
-139.1%
(Below Avg)
Profit Margin
29.28%
This Stock
vs
-20.78%
Sector Avg
-240.9%
(Weaker)
Debt to Equity
0.21
This Stock
vs
6.16
Sector Avg
-96.5%
(Less Debt)
Revenue Growth
8.4%
This Stock
vs
137.39%
Sector Avg
-93.9%
(Slower)
Current Ratio
5.76
This Stock
vs
3.36
Sector Avg
+71.3%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AUPH
Aurinia Pharmaceuticals Inc.
|
NEUTRAL | $1.92B | 26.42 | 20.7% | 29.3% | $14.53 | |
|
ATRC
AtriCure, Inc.
|
NEUTRAL | $1.94B | - | -6.1% | -5.6% | $39.07 | |
|
ADUS
Addus HomeCare Corporation
|
NEUTRAL | $1.88B | 19.42 | 9.3% | 6.7% | $101.35 | |
|
ANAB
AnaptysBio, Inc.
|
BULLISH | $1.86B | - | -24.5% | -5.6% | $64.81 | |
|
AZTA
Azenta, Inc.
|
NEUTRAL | $1.84B | 77.02 | 1.4% | -9.4% | $40.05 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-02 | MILLER JOSEPH M | Chief Financial Officer | Stock Award | 49,038 | - |
| 2026-01-02 | GREENLEAF PETER S | Chief Executive Officer | Stock Award | 165,384 | - |
| 2026-01-02 | DONLEY MATTHEW MAXWELL | Chief Operating Officer | Stock Award | 54,166 | - |
| 2026-01-02 | ROBERTSON STEPHEN P | General Counsel | Stock Award | 48,558 | - |
| 2025-08-05 | TANG KEVIN C | Director | Purchase | 1,300,000 | $13,590,000 |
| 2025-08-01 | KEENAN GREG | Officer | Sale | 20,000 | $210,000 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
6 analysts
Leerink Partners
2025-12-03
Outperform
Market Perform
Jefferies
2025-11-07
Hold
Buy
RBC Capital
2025-11-05
Outperform
Sector Perform
RBC Capital
2025-08-01
Outperform
Outperform
Past News Coverage
Recent headlines mentioning AUPH from our newsroom.
Newest → oldest
No matching news yet.